Jilin Aodong Pharmaceutical Group Co., Ltd. Class A
SSZSE:00062316.89
CNY
+0.07
(+0.42%)
ISIN
CNE000000719
Return %
Stock
S&P 500
1Y
-17.61
13.14
3Y
7.17
80.78
5Y
1.50
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Shu Qin Guo
- Full Time Employees
- 5,461
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 2158 Aodong Street Dunhua JI China 133700
- IPO Date
- Oct 28, 1996
- Website
- jlaod.com
- Similar Companies
- Business
- Jilin Aodong Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products with a strong focus on traditional Chinese medicine (TCM) and Western pharmaceuticals. The company's main products include prescription medications, over-the-counter drugs, oral liquid solutions, injections, capsules, granules, tablets, Chinese herbal medicines, powders, tonic medicines, enzymes, biochemical medicines, and plant chemical medicines. Key branded products include Calming the Brain Solution, Pediatric Chai Gui Antipyretic Oral Solution, Blood Enhancing Drink Oral Liquid, Ribonucleic Acid for Injection, Pingyangmycin Hydrochloride for Injection, Astragalus Hypoglycemic Capsules, Adenosylmethionine Butanedisulfonate for Injection, Muscle Extender Tablets, and Jinlianhua Oral Liquid, among others. The company also produces pharmaceutical excipients, packaging materials, enzyme stock solutions, ginseng and antler products, health care products, and processes edible agricultural products. Its product range covers therapeutic areas such as cardiovascular, women and children medication, liver, gallbladder, and stomach care, antipyretic and analgesic, rheumatic bone disease, antibacterial and anti-inflammatory, cough and phlegm relief, and urinary medication. Beyond pharmaceuticals, the company operates in related sectors including highway construction and toll collection, animal husbandry, specialty chemicals manufacturing, and utility services such as heat and water supply. Founded in 1957, Jilin Aodong is headquartered in Dunhua, Jilin Province, China, and exports products to over 20 countries including the United States, Canada, and Southeast Asia. Recent major company changes include a continued strategic emphasis on digital transformation and innovation in drug development, with investments in telemedicine and artificial intelligence technologies to address modern healthcare challenges. In 2022, Jilin Aodong launched 10 new products primarily targeting respiratory and digestive health. The company has also expanded its international footprint and diversified its business portfolio to stabilize revenue streams amid industry volatility. It has maintained a stable return on equity around 15.2% over recent years and demonstrated strong liquidity positioning. Jilin Aodong continues to pursue international collaborations and innovative R&D initiatives while sustaining its commitment to integrating traditional practices with modern scientific approaches to enhance efficacy and safety in pharmaceutical products. The executive and management teams consist of experienced industry veterans who retain significant control over strategic direction. This comprehensive approach positions Jilin Aodong as a leading pharmaceutical and healthcare company in China with growing global ambitions.